Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benmelstobart and Anlotinib Neoadjuvant Therapy in HNSCC
NCT06699498Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Dec 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in head and neck squamous cell carcinoma (HNSCC), sponsored by Jiangsu Provincial People's Hospital. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06699498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06699498.